Bausch Health Companies Inc. · TSX:BHC

Bausch Health Companies — 38th Annual J.P. Morgan Healthcare Conference 2020

12 slides from Bausch Health Companies's conference presentation, Jan 13, 2020

  1. Slide 1: Bausch Health: 20/20 Vision

    38 th Annual J.P. Morgan Healthcare Conference Jan. 13, 2020 Bausch Health: 20/20 VISION A Global, Diversified Health Care Company with Independently Strong Businesses Positioned for the Next Decade

  2. Slide 2: Forward-looking statements

    2 This presentation contains forward - looking information and statements, within the meaning of applicable securities laws (collectively, “forward - looking statements”), including, but not limited to, statements regarding Bausch Health's future prospects and performance (including targeted three -

  3. Slide 3: Non-GAAP financial measures

    3 To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non - GAAP financial measures including ( i ) Adjusted EBITDA, (ii) Organic Revenue Growth and (iii) Constant Currency. Management uses some of these non

  4. Slide 4: Bausch Health 20/20 Vision: Global, Diversified, Durable

    4 1. See Slide 3 for further non - GAAP information. The reconciliations of these historic non - GAAP measures and additional non - GAAP in formation to the most directly comparable financial measures calculated and presented in accordance with GAAP are in our 3Q19 earnings presentation available on

  5. Slide 5: Bausch Health: 20/20 Vision

    5 Bausch Health: 20/20 Vision Grow by gaining market share and capitalizing on global megatrends Deliver on 3 - year CAGRs 2 (constant currency and from the mid - point of 2019 guidance 1 ) • Expect revenue to grow at a 4% - 6% CAGR • Expect adj. EBITDA (non - GAAP) 3 to grow at a 5% - 8% CAGR Enhan

  6. Slide 6: Global Eye Health Driven by Megatrends and New Products

    Global Eye Health Driven by Megatrends and New Products Myopia Epidemic • Myopia is a risk factor for glaucoma, macular degeneration and retinal detachment 1 • 40% of North Americans are affected by myopia; the number of cases doubled between 1972 and 2004 2 • 42% of adults age 25 to 29 years old in

  7. Slide 7: GI Driven by Megatrends, Globalization and New Products

    GI Driven by Megatrends, Globalization and New Products Increasing Importance of Microbiome • IBS is thought to be derived from the microbiome 1 • 12% prevalence of IBS in the general global population 1 • Patients with IBS account for increased resource utilization and decreased productivity compar

  8. Slide 8: Evolution of Dermatology Being Driven By Physicians and Consumers

    Evolution of Dermatology Being Driven By Physicians and Consumers Growing Market Demand • ~9,600 dermatologists practicing in the U.S. in 2017; only enough to properly service 50% of the country’s population 6 • Global telemedicine valued at ~$14.8B in 2016 with telederm the largest portion at 30% 7

  9. Slide 9: Durable Growth Franchises 2020 & Beyond

    • Continued strong performance in global vision care franchises • LUMIFY ® market share gains • Ramp of SiHy daily in Japan and launch in U.S./EU/rest of world • Extended Depth of Focus (EDOF) on Akreos ® platform • Increase e - commerce presence on Amazon and Alibaba • Continued strong XIFAXAN ® gr

  10. Slide 10: NOV03: Recently Licensed Innovative Opportunity for Dry Eye Disease

    NOV03: Recently Licensed Innovative Opportunity for Dry Eye Disease 1. Dry eye disease. 2. Territory for both treatments and future development is the United States and Canada. 3. Farrand et al. Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older. Am J O

  11. Slide 11: R&D pipeline and expected milestones

    1. Investigational device exemption 2. Exclusive licensing agreement with Clearside Biomedical, Inc. 3. Overt hepatic encephalopathy. 4. Small intestinal bacterial overgrowth. 5. Study being run by partner, Alfasigma S.p.A. 6. Sphingosine 1 - phosphate. 11 • SiHy Daily – Launched in Japan; U.S. laun

  12. Slide 12: 2019 accomplishments by franchise

    Bausch + Lomb/International x Launched Bausch + Lomb ULTRA ® Multi - Focal for Astigmatism x Launched Zen Multifocal and Tangible Science Hydra - PEG ® coating x Launched PreserVision ® AREDS2 Formula Minigel Eye Vitamins x Launched Ocuvite ® eye performance x Launched LOTEMAX ® SM x Continued expan

Bausch Health Companies — 38th Annual J.P. Morgan Healthcare Conference 2020 on 6ix